Hydroxysafflor yellow A alleviates high fat diet induced hyperlipidemia and improves host intestinal environment via hepatic signaling regulation
Abstract
Hyperlipidemia is a metabolic disorder characterized by abnormally elevated circulating lipid levels and is closely associated with host metabolic homeostasis. In this study, we integrated network pharmacology, in vivo and in vitro experiments to investigate the lipid-lowering effects and mechanisms of hydroxysafflor yellow A (HSYA), the major bioactive component of Carthamus tinctorius L. HSYA significantly ameliorated HFD-induced metabolic abnormalities, including body weight gain, dyslipidemia, and hepatic steatosis, reduced serum levels of total cholesterol (TC), low-density lipoprotein cholesterol, alanine aminotransferase, aspartate aminotransferase, and lipopolysaccharide, enhanced hepatic superoxide dismutase activity, and suppressed tumor necrosis factor-α, interleukin-6, and interleukin-1β. 16S rRNA sequencing revealed that HSYA restored gut microbiota homeostasis, increased beneficial bacteria such as Bacteroidota and Verrucomicrobiota, and upregulated intestinal barrier proteins zonula occludens-1 and occludin. Network pharmacology indicated close associations among HSYA, hyperlipidemia, gut microbiota, and metabolites, and identified the PI3K/AKT/HIF-1α pathway as a key mediator, with gut microbiota and intestinal barrier restoration as related mechanisms. In vitro, HSYA exhibited no cytotoxicity and reduced TC, triglycerides (TG), and lipid droplets in palmitic acid-treated HepG2 cells, confirming its metabolic benefits. Thus, HSYA may alleviate HFD-induced dyslipidemia and hepatic steatosis through PI3K/AKT/HIF-1α and gut–liver axis modulation, supporting its clinical potential in metabolic diseases.
Related
- Pediococcus acidilactici Long21 Alleviates Intestinal Sensitivity and Improves Gut Health in German Shepherd Dogs by Regulating Intestinal Metabolic Profiles
- Ketogenic diet alleviates acute radiation-induced intestinal injury through JAK2/STAT3/RORγt/IL-17A signaling pathway via gut microbiome
- Resistant maltodextrin favorably alters the intestinal environment, short-chain fatty acids, and intestinal bacteria in healthy humans
- Regulation of Intestinal P-Glycoprotein by Gamma-Ray Irradiation: Impacts on Transporter Expression and Oxidative Stress
- Novel index for assessing the intestinal environment in prebiotic-supplemented healthy adults via non-invasive gas analysis
BibTeX
@article{xu2026hydroxysafflor,
title = {{Hydroxysafflor yellow A alleviates high fat diet induced hyperlipidemia and improves host intestinal environment via hepatic signaling regulation}},
author = {Caiyou Xu and Keman Ji and Haoran Li and Jiabo Zhang and Manping Wu and Chao Chen and Ruge Niu and Yuan Sun and Chunling Liu},
journal = {Scientific Reports},
year = {2026},
month = oct,
doi = {10.1038/s41598-026-67572-0},
url = {https://www.nature.com/articles/s41598-026-67572-0},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Hydroxysafflor yellow A alleviates high fat diet induced hyperlipidemia and improves host intestinal environment via hepatic signaling regulation
AU - Caiyou Xu
AU - Keman Ji
AU - Haoran Li
AU - Jiabo Zhang
AU - Manping Wu
AU - Chao Chen
AU - Ruge Niu
AU - Yuan Sun
AU - Chunling Liu
PY - 2026
DA - 2026/10/10
JO - Scientific Reports
DO - 10.1038/s41598-026-67572-0
UR - https://www.nature.com/articles/s41598-026-67572-0
AB - Hyperlipidemia is a metabolic disorder characterized by abnormally elevated circulating lipid levels and is closely associated with host metabolic homeostasis. In this study, we integrated network pharmacology, in vivo and in vitro experiments to investigate the lipid-lowering effects and mechanisms of hydroxysafflor yellow A (HSYA), the major bioactive component of Carthamus tinctorius L. HSYA significantly ameliorated HFD-induced metabolic abnormalities, including body weight gain, dyslipidemia, and hepatic steatosis, reduced serum levels of total cholesterol (TC), low-density lipoprotein cholesterol, alanine aminotransferase, aspartate aminotransferase, and lipopolysaccharide, enhanced hepatic superoxide dismutase activity, and suppressed tumor necrosis factor-α, interleukin-6, and interleukin-1β. 16S rRNA sequencing revealed that HSYA restored gut microbiota homeostasis, increased beneficial bacteria such as Bacteroidota and Verrucomicrobiota, and upregulated intestinal barrier proteins zonula occludens-1 and occludin. Network pharmacology indicated close associations among HSYA, hyperlipidemia, gut microbiota, and metabolites, and identified the PI3K/AKT/HIF-1α pathway as a key mediator, with gut microbiota and intestinal barrier restoration as related mechanisms. In vitro, HSYA exhibited no cytotoxicity and reduced TC, triglycerides (TG), and lipid droplets in palmitic acid-treated HepG2 cells, confirming its metabolic benefits. Thus, HSYA may alleviate HFD-induced dyslipidemia and hepatic steatosis through PI3K/AKT/HIF-1α and gut–liver axis modulation, supporting its clinical potential in metabolic diseases.
SN - 2045-2322
ER -